Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention
Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention
复制标题
DOI：
10.1016/j.ehj.2003.08.013
复制
发表时间：
2003-11-01
影响因子：
39.3
通讯作者：
Tai, HC
中科院分区：
文献类型：
--
作者：
Lu, TM;Ding, YA;Tai, HC
目的探讨非对称二甲基精氨酸（ADMA）血药浓度对经皮冠状动脉介入治疗（PCI）患者临床预后的预测价值。方法与结果对153例连续行PCI治疗的稳定型心绞痛患者进行前瞻性临床随访。术前用高效液相色谱法测定血浆ADMA水平。主要心血管不良事件包括心血管性死亡、心肌梗死和靶血管重复血运重建。根据血浆ADMA水平将患者分为各组。在16个月的随访期间（中位），6例I型不孕患者发生心血管事件（0.62 muM）， P
Aims We investigated the predictive value of plasma concentration of asymmetrical dimethylarginine (ADMA) on clinical outcome in patients undergoing percutaneous coronary intervention (PCI).Methods and results One-hundred and fifty-three consecutive patients with stable angina and undergoing PCI were prospectively enrolled for clinical follow-up. Plasma ADMA levels were determined before procedure by high performance liquid chromatography. The major adverse cardiovascular events included cardiovascular death, myocardial infarction, and repeat revascularization of target vessels. Patients were grouped into tertiles according to their plasma ADMA levels. Over a follow-up period of 16 months (median), cardiovascular events occurred in 6 patients of tertile I (0.62 muM), P